Retrophin Signs US License Agreement for Syntocinon Nasal Spray with Novartis
December 12, 2013 at 07:23 AM EST
Retrophin, Inc. (OTC: RTRX ) today announced that it has signed an agreement with Novartis Pharma AG (NYSE: NVS ) for an exclusive U.S. license for Syntocinon™ Nasal Spray, the intranasal formulation
